Updated BEXMAB data in frontline HR-MDS shows complete remission rate substantially increased to 43% August 11, 2025
NMPA accepts supplementary NDA for Toripalimab in 1L HER2-expressing Urothelial Carcinoma August 11, 2025
FDA & NMPA’s approval to initiate Ph 2 COMPASSION-36/AK104-225 registrational trial of cadonilimab + lenvatinib combo in IO-refractory HCC announced August 11, 2025
FDA Grants Priority Review to Breyanzi (lisocabtagene maraleucel) for R/R Marginal Zone Lymphoma August 11, 2025
Positive Feedback Received from FDA on Late-Stage Clinical Development of Eftilagimod Alfa in Head and Neck Cancer with CPS <1 August 11, 2025
Regulatory Clearance obtained to Initiate Ph 1 Trial for PQ203 in the U.S. and Canada; FDA Fast Track Designation Granted August 11, 2025
FDA Clears IND for KTX-2001 in metastatic CRPC; Clinical Trial Collaboration with Bayer for Supply of Darolutamide announced August 11, 2025
FDA clears IND for Ph 2 trials for RC148 in multiple advanced malignant solid tumors in the US August 11, 2025
U.S. FDA Approves Modeyso™ (dordaviprone) for Recurrent H3 K27M-mutant Diffuse Midline Glioma August 11, 2025
